Previous BCG vaccination is associated with less severe clinical progression of COVID-19

dc.contributor.authorPereira, Susan Martins
dc.contributor.authorBarreto, Florisneide Rodrigues
dc.contributor.authorSouza, Ramon Andrade de
dc.contributor.authorSantos, Carlos Antonio de Souza Teles
dc.contributor.authorPereira, Marcos
dc.contributor.authorPaixão, Enny Santos da
dc.contributor.authorLima, Carla Cristina Oliveira de Jesus
dc.contributor.authorNatividade, Marcio Santos da
dc.contributor.authorLindoso, Ana Angélica Bulcão Portela
dc.contributor.authorFernandes, Eder Gatti
dc.contributor.authorJunior, Evonio Barros Campelo
dc.contributor.authorPescarini, Julia Moreira
dc.contributor.authorAndrade, Kaio Vinicius Freitas de
dc.contributor.authorSouza, Fernanda Mattos de
dc.contributor.authorBritto, Elisangela Alves de
dc.contributor.authorNunes, Ceuci
dc.contributor.authorIchihara, Maria Yuri
dc.contributor.authorDalcolmo, Margareth
dc.contributor.authorTrajman, Anete
dc.contributor.authorBarral‐Netto, Manoel
dc.contributor.authorAbubakar, Ibrahim
dc.contributor.authorBarreto, Mauricio Lima
dc.contributor.authorXimenes, Ricardo Arraes de Alencar
dc.contributor.authorRodrigues, Laura Cunha
dc.date.accessioned2024-12-16T12:52:49Z
dc.date.available2024-12-16T12:52:49Z
dc.date.issued2023
dc.description.abstractBackground BCG vaccination, originally used to prevent tuberculosis, is known to “train” the immune system to improve defence against viral respiratory infections. We investigated whether a previous BCG vaccination is associated with less severe clinical progression of COVID-19 Methods A case-control study comparing the proportion with a BCG vaccine scar (indicating previous vaccination) in cases and controls presenting with COVID-19 to health units in Brazil. Cases were subjects with severe COVID-19 (O2 saturation < 90%, severe respiratory efort, severe pneumonia, severe acute respiratory syndrome, sepsis, and sep‐ tic shock). Controls had COVID-19 not meeting the defnition of “severe” above. Unconditional regression was used to estimate vaccine protection against clinical progression to severe disease, with strict control for age, comorbidity, sex, educational level, race/colour, and municipality. Internal matching and conditional regression were used for sensitivity analysis. Results BCG was associated with high protection against COVID-19 clinical progression, over 87% (95% CI 74–93%) in subjects aged 60 or less and 35% (95% CI −44–71%) in older subjects. Conclusions This protection may be relevant for public health in settings where COVID-19 vaccine coverage is still low and may have implications for research to identify vaccine candidates for COVID-19 that are broadly protec‐ tive against mortality from future variants. Further research into the immunomodulatory efects of BCG may inform COVID-19 therapeutic research.
dc.identifier.citationPereira SM, Barreto FR, de Souza RA, de Souza Teles Santos CA, Pereira M, da Paixão ES, de Jesus Lima CCO, da Natividade MS, Lindoso AABP, Fernandes EG, Junior EBC, Pescarini JM, de Andrade KVF, de Souza FM, de Britto EA, Nunes C, Ichihara MY, Dalcolmo M, Trajman A, Barral-Netto M, Abubakar I, Barreto ML, de Alencar Ximenes RA, Rodrigues LC. Previous BCG vaccination is associated with less severe clinical progression of COVID-19. BMC Med. 2023 Apr 13;21(1):145. doi: 10.1186/s12916-023-02859-x.
dc.identifier.otherDOI: 10.1186/s12916-023-02859-x
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/725
dc.language.isoen
dc.publisherBMC Medicine
dc.subjectBCGen
dc.subjectBacillus Calmette-Guérinen
dc.subjectCOVID-19en
dc.subjectSARS-CoV-2en
dc.subjectCoronavirus disease 2019en
dc.subjectSeverityen
dc.subjectVaccination.en
dc.titlePrevious BCG vaccination is associated with less severe clinical progression of COVID-19
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Pereira SM et al_BMC Medicine.pdf
Tamanho:
257.34 KB
Formato:
Adobe Portable Document Format
Descrição:
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição: